Theresa Keegan, PhD, MS, associate professor, hematology and oncology, University of California at Davis Comprehensive Cancer Center, outlines barriers and facilitators to clinical trial participation among adolescents and young adults (AYAs).
Theresa Keegan, PhD, MS, associate professor, hematology and oncology, University of California at Davis Comprehensive Cancer Center, outlines barriers and facilitators to clinical trial participation among adolescents and young adults (AYAs).
TranscriptWhat are some barriers and facilitators to clinical trial participation among adolescents and young adults (AYAs)?
There’s a number of barriers, and we really focus on barriers in our session, mostly because of the low overall trial enrollment rate. Some facilitators is that there’s a hope for clinical benefit or just general altruism. But, I think in terms of barriers, it’s much more complex, and it really starts kind of at the structural level. Are there clinical trials available nationally, and are they available at a particular institution? Those are sort of the initial barriers. And then, is a patient eligible for that particular trial? Are there age restrictions that warrant this patient or specific characteristics of their cancer that make them ineligible?
The next sort of level of barriers are provider-level barriers. These are really the providers knowing about available clinical trials, communicating research with AYAs, and their ability to do so in order for them to understand what they’re getting into with a clinical trial.
And then I would say the patient-level barriers. Those are also pretty substantial for AYAs, and those include things like concerns about the side effects that may occur with clinical trials, concerns about prolonged hospitalizations, general concerns about experimentation, actually, and lack of peer support. I would say unique to AYAs is that they’re very concerned with the extra time that the treatment would involve if they were to participate on a clinical trial.
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from the Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen